Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUMIT: Selumetinib plus dacarbazine vs placebo plus dacarbazine in metastatic uveal melanoma
2013-003545-41Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in intraocular melanoma and Malignant melanoma of other specified sites (MM) comparing Selumetinib plus dacarbazine with Placebo plus dacarbazine (2 arms). Primary endpoint: Progression-free survival by BICR (RECIST 1.1). Started Nov 2013; status: completed.
02
Drugs
selumetinib
03
Conditions
intraocular melanomaMalignant melanoma of other specified sites (MM)
Beyond the preview
Go deeper on 2013-003545-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003545-41.